Keywords: itp, patients, achieve, platelet, response, nplate, biotechnology
74% of ITP patients achieve platelet response on Nplate
Article | 15 December 2008
US biotechnology firm Amgen reported strong data from an ongoing, open-label extension study of Nplate (romiplostim) in chronic immune thrombocytopenic ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
